Trial intelligence / Profile preview

Isatuximab + VCd followed by isatuximab + lenalidomide maintenance in newly diagnosed multiple myeloma with severe renal impairment

2024-516061-36-00Phase 2Completed

Sponsor: Hellenic Society of Hematology
Start: Dec 2024
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of isatuximab, bortezomib, cyclophosphamide, dexamethasone and lenalidomide in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Renal response rate at 6 months. Started Dec 2024; status: completed.

Drugs

isatuximabbortezomibcyclophosphamidedexamethasonelenalidomide

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2024-516061-36-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516061-36-00.